New Publication: Thymosin Alpha-1 Plus Chemotherapy in Gastric Cancer

On September 18, 2026, Frontiers in Immunology published a new paper titled "Efficacy and safety of thymosin α1 combined with chemotherapy for gastric cancer: a systematic review and meta-analysis of randomized controlled trials." The publication is a systematic review and meta-analysis of randomized controlled trials examining thymosin alpha-1 used alongside chemotherapy in gastric cancer. Thymosin alpha-1 remains classified as unapproved for this or other clinical uses in this context, and its use here is a research subject rather than an approved therapy. No specific findings, outcome data, or conclusions from the paper are detailed here. This brief reports only that the publication exists, its title, its journal, and its date of release. Readers interested in the specific results, methodology, or statistical findings should consult the original publication directly through the listed source. As with all meta-analyses of randomized controlled trials, the paper is expected to synthesize data across multiple studies, though the specific scope and conclusions are not described in this summary. For additional background on thymosin alpha-1, including its regulatory status and general research context, see the compound overview.